# Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

> **NCT02306954** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Providence Health & Services** · enrollment: 84 (estimated)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** High Dose IL-2
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT02306954
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-12
- **Primary completion:** 2020-09-15
- **Final completion:** 2026-12
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02306954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02306954, "Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02306954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*